Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD
Jae‐Won Hyun(Seoul National University Hospital), Ho Jin Kim(National Cancer Center), Ha Young Shin(Yonsei University), Woojun Kim(National Cancer Center), So‐Young Huh(Kosin University Gospel Hospital), Su‐Hyun Kim(National Cancer Center), Jae-Hong Park(Dong-A University Hospital), Seung Woo Kim(Ulsan College), Ki Hoon Kim(Inje University Sanggye Paik Hospital), Hye Lim Lee(Korea University Medical Center), Ju‐Hong Min(Samsung Medical Center), Byoung Joon Kim(Samsung Medical Center), Ji Won Seo(National Cancer Center), Jiah Kim(Samsung Medical Center)
Cited by 22
Related Papers
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Neuromyelitis optica
|Nature Reviews Disease Primers|2020|464
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284
A New Subtype Classification of Ischemic Stroke Based on Treatment and Etiologic Mechanism
|European Neurology|2006|121